Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 3/2020

01-03-2020 | Thyroid Disease | Editorial

Errare humanum est, sed in errare perseverare diabolicum: methodological errors in the assessment of the relationship between I-131 therapy and possible increases in the incidence of malignancies

Authors: Frederik A. Verburg, Martha Hoffmann, Ioannis Iakovou, Mark W. Konijnenberg, Jasna Mihailovic, Pablo Minguez Gabina, Petra Petranović Ovčariček, Cristoph Reiners, Alexis Vrachimis, Slimane Zerdoud, Luca Giovanella, Markus Luster

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 3/2020

Login to get access

Excerpt

For nearly eight decades [1] now, radioactive iodine (RAI) therapy has been playing an important role in the treatment of benign thyroid diseases (BTD) as well as differentiated thyroid cancer (DTC) [2]. …
Literature
1.
Hertz S, Roberts A. Application of radioactive iodine in Graves disease. J Clin Invest. 1942;21:624.
2.
Seidlin SM, Marinelli LD, Oshry E. Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroid. JAMA. 1946;132:838–47.CrossRef
3.
Seidlin SM, Siegal E, Yalow AA, Melamed S. Acute myeloid leukemia following prolonged iodine-131 therapy for metastatic thyroid carcinoma. Science. 1956;123:800–1.CrossRef
4.
Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Therapy, Nucl Med. 1962;87:171–82.
5.
Eberlein U, Scherthan H, Bluemel C, Peper M, Lapa C, Buck AK, et al. DNA Damage in peripheral blood lymphocytes of thyroid cancer patients after radioiodine therapy. J Nucl Med. 2016;57:173–9.CrossRef
6.
Verburg FA, Luster M, Lassmann M, Reiners C. (131) I therapy in patients with benign thyroid disease does not conclusively lead to a higher risk of subsequent malignancies. Nuklearmedizin. 2011;50:93–9.CrossRef
7.
Molenaar RJ, Sidana S, Radivoyevitch T, Advani AS, Gerds AT, Carraway HE, et al. Risk of hematologic malignancies after radioiodine treatment of well-differentiated thyroid cancer. J Clin Oncol. 2018;36:1831–9.CrossRef
8.
Molenaar RJ, Pleyer C, Radivoyevitch T, Sidana S, Godley A, Advani AS, et al. Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine. Leukemia. 2018;32:952–9.CrossRef
9.
Kitahara CM, Berrington de Gonzalez A, Bouville A, Brill AB, Doody MM, Melo DR, et al. Association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism. JAMA Intern Med. 2019;179:1034.CrossRef
10.
Verburg FA, Giovanella L, Iakovou I, Konijnenberg MW, Langsteger W, Lassmann M, et al. I-131 as adjuvant treatment for differentiated thyroid carcinoma may cause an increase in the incidence of secondary haematological malignancies: an “inconvenient” truth? Eur J Nucl Med Mol Imaging. 2018;45:2247–9.CrossRef
11.
Piccardo A, Puntoni M, Verburg FA, Luster M, Giovanella L. Power of absolute values to avoid data misinterpretations: the case of radioiodine-induced leukemia and myelodysplasia. J Clin Oncol. 2018;36:1880–1.CrossRef
12.
Hindié E, Récher C, Zerdoud S, Leenhardt L, Avram AM. Risk of hematologic malignancies after radioactive iodine treatment of thyroid cancer: an unjustified warning. J Clin Oncol. 2018;36:1881–2.CrossRef
13.
Tulchinsky M, Baum RP, Bennet KG, Freeman LM, Jong I, Kairemo K, et al. Well-founded recommendations for radioactive iodine treatment of differentiated thyroid cancer require balanced study of benefits and harms. J Clin Oncol. 2018;36:1887–8.CrossRef
14.
Ron E, Doody MM, Becker DV, Brill AB, Curtis RE, Goldman MB, et al. Cancer mortality following treatment for adult hyperthyroidism. JAMA. 1998;280:347–55.CrossRef
15.
Chen Y-K, Lin C-L, Chang Y-J, Cheng FT-F, Peng C-L, Sung F-C, et al. Cancer risk in patients with Graves’ disease: a nationwide cohort study. Thyroid. 2013;23:879–84.CrossRef
16.
Krashin E, Piekiełko-Witkowska A, Ellis M, Ashur-Fabian O. Thyroid hormones and cancer: a comprehensive review of preclinical and clinical studies. Front Endocrinol (Lausanne). 2019;10:59.CrossRef
17.
Khan SR, Chaker L, Ruiter R, Aerts JGJV, Hofman A, Dehghan A, et al. Thyroid function and cancer risk: the Rotterdam study. J Clin Endocrinol Metab. 2016;101:5030–6.CrossRef
18.
Tulchinsky M, Brill AB. Spotlight on the association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism is keeping the highest risk from antithyroid drugs in the blind spot. Clin Nucl Med. 2019;44:789–91.CrossRef
19.
Verburg FA, Dietlein M, Lassmann M, Luster M, Reiners C. Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2009;36:343–6.CrossRef
Metadata
Title
Errare humanum est, sed in errare perseverare diabolicum: methodological errors in the assessment of the relationship between I-131 therapy and possible increases in the incidence of malignancies
Authors
Frederik A. Verburg
Martha Hoffmann
Ioannis Iakovou
Mark W. Konijnenberg
Jasna Mihailovic
Pablo Minguez Gabina
Petra Petranović Ovčariček
Cristoph Reiners
Alexis Vrachimis
Slimane Zerdoud
Luca Giovanella
Markus Luster
Publication date
01-03-2020
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2020
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-019-04580-5

Other articles of this Issue 3/2020

European Journal of Nuclear Medicine and Molecular Imaging 3/2020 Go to the issue

Original Article

Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with 68Ga-PSMA-11 PET/MRI in men with treatment-naïve prostate cancer

Short Communication

Planar scan vs. SPECT/low-dose CT for estimating split renal function by 99mTc-DMSA scintigraphy in children

Original Article

Digital versus analogue PET in [68Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer: a matched-pair comparison

Image of the Month

Extranodal involvement of multiple organs in diffuse large B cell lymphoma detected on 18F-FDG PET/CT

Editorial

Radiology and nuclear medicine: advancing together in the era of precision medicine

Original Article

225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience